Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of end-stage renal disease and slow the progression of nephropathy, but they do not appear to decrease all-cause or cardiovascular mortality in people with Type 2 diabetes and proteinuria. 31407377 2020
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.600 Biomarker disease BEFREE The Protective Role of Adiponectin for Lipoproteins in End-Stage Renal Disease Patients: Relationship with Diabetes and Body Mass Index. 30911344 2019
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.600 AlteredExpression disease BEFREE In conclusion, higher adiponectin levels are associated with a higher risk of ESRD independent of conventional risk factors, BMI, and metabolic syndrome components. 31323071 2019
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.600 AlteredExpression disease BEFREE MCP-1 expression in endothelial cells treated with uremic serum from ESRD patients with hypertension only was significantly increased compared with its expression in other cohorts. 31312972 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE This meta-analysis suggested that I/D polymorphism of ACE can markedly increase the incidence of diabetes-related end-stage renal disease, especially in Asian populations. 30840289 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE The C allele in rs5186 in AGTR1 was associated with higher rates of death and major cardiovascular events in a meta-analysis of EA and AfAn patients with end-stage kidney disease.SNPs in ACE were associated with SCD. 29982608 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Angiotensin-converting enzyme inhibitors can remarkably delay the development of ESRD. 30128941 2019
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.600 GeneticVariation disease BEFREE Comparison of the <i>MCP-1</i> gene polymorphism distribution in ESRD patients with various primary diseases leading to ESRD did not show any significant differences. 31847640 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE Compared with DPP4i nonusers, DPP4i users had a lower risk of ESRD (hazard ratio, 0.81; 95% CI, 0.70-0.94; P=.04) and all-cause mortality (hazard ratio, 0.28; 95% CI, 0.23-0.34; P<.001) after adjustments for CKD, advanced CKD, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use. 30343892 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE This meta-analysis aims to assess the benefits of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) supplemented with <italic>Rheum officinale</italic> for delaying the progression of chronic renal failure. 29208203 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (compared to other antihypertensive agents) was associated with a lower risk for eGFR <45 mL/min/1.73m², HR 0.64 (95% confidence interval [CI] 0.45-0.9), P = .01, and also less ESRD; HR 0.03 (95% CI 0.001-0.20), P = .004. 29498216 2018
Entrez Id: 7040
Gene Symbol: TGFB1
TGFB1
0.600 AlteredExpression disease BEFREE Decreased expression of transforming growth factor-β1 and α-smooth muscle actin contributes to the protection of lotensin against chronic renal failure in rats. 30371125 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 AlteredExpression disease BEFREE Additionally, BPS reduced the levels of MDA while increasing the levels of SOD, ACE activity, and AT1 expression in the renal tissues of CRF rats. 30078019 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE For renal outcomes, ARBs significantly reduced the risk of ESRD by 23% (odds ratio 0.77, 95%CI 0.65-0.92), while ACE inhibitors were not associated with a decreased risk of ESRD (0.69, 0.43-1.10). 29794446 2018
Entrez Id: 7040
Gene Symbol: TGFB1
TGFB1
0.600 Biomarker disease BEFREE <b>Aims/Hypothesis:</b> Transforming growth factor-beta (TGF-β1) plays an important regulatory role in the progression of chronic kidney failure. 30618784 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE The association between the use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) and mortality in end-stage renal disease (ESRD) patients lacks sufficient evidence. 29808610 2018
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.600 AlteredExpression disease BEFREE In both type 1 and type 2 diabetes (T2D) patients with DKD, elevated adiponectin serum levels have been observed, and adiponectin serum level is a prognostic factor of end-stage renal disease. 28402446 2017
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.600 AlteredExpression disease BEFREE Pooled analysis of GENEDIAB and GENESIS studies showed that baseline plasma adiponectin levels were higher in subjects with established/advanced DN at inclusion (P < 0.0001) and in subjects who developed end-stage renal disease (ESRD) at follow-up (P < 0.0001). 28499019 2017
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.600 Biomarker disease BEFREE The associations between elevated adiponectin and end-stage renal disease are well recognized and thought to be at least partially explained by reduced renal clearance. 27368123 2017
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.600 AlteredExpression disease BEFREE Osthole treatment significantly attenuated the protein expression of transforming growth factor‑β1 (TGF‑β1), reduced monocyte chemoattractant protein‑1 activity and increased the phosphoinositide 3‑kinase (PI3K)/protein kinase B (Akt) ratio in CRF rats. 28765904 2017
Entrez Id: 7040
Gene Symbol: TGFB1
TGFB1
0.600 Biomarker disease BEFREE These results suggested that osthole protects against inflammation in a rat model of CRF via suppression of NF‑κB and TGF‑β1, and activation of PI3K/Akt/nuclear factor (erythroid‑derived 2)‑like 2 signaling. 28765904 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE End-stage renal disease and adherence to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among patients with diabetes. 28177196 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker disease BEFREE <b>Objective</b> To examine long term cardiorenal outcomes associated with increased concentrations of creatinine after the start of angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment.<b>Design</b> Population based cohort study using electronic health records from the Clinical Practice Research Datalink and Hospital Episode Statistics.<b>Setting</b> UK primary care, 1997-2014.<b>Participants</b> Patients starting treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers (n=122 363).<b>Main outcome measures</b> Poisson regression was used to compare rates of end stage renal disease, myocardial infarction, heart failure, and death among patients with creatinine increases of 30% or more after starting treatment against those without such increases, and for each 10% increase in creatinine. 28279964 2017
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.600 Biomarker disease BEFREE Furthermore, H<sub>2</sub>S decreased the expression levels of tumor necrosis factor-α, interleukin (IL)-6, IL-10, and monocyte chemoattractant protein-1, as well as the protein levels of p50, p65, and p-p65 in the kidney of CRF rats. 28352125 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation disease BEFREE Our study sought to examine whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) could reduce the frequencies of cardiovascular and cerebrovascular events in patients receiving hemodialysis using the medication possession ratio (MPR) method of analysis.This retrospective cohort study identified cases of ESRD with dialysis from the National Health Insurance Research Database between 1999 and 2006, and used Cox-regression methods to evaluate risk of poor outcomes. 28353612 2017